GlassScriptPhysician profile
Jonathan Alta Herbst
NPI 1538188602
$28,871.90
in general payments reported to CMS, 2019-2025
34 companies · $6,517 in 2025
The $6,517 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,640 · 2020: $3,186 · 2021: $5,429 · 2022: $2,567 · 2023: $2,839 · 2024: $4,694 · 2025: $6,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,041.03 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,718.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,626.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $3,134.08 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $2,908.81 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $1,997.88 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lilly USA, LLC | $1,949.02 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Amgen INC. | $913.40 | 2019-2025 | Otezla, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $841.49 | 2019-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $645.00 | 2024-2025 | Cobenfy, Camzyos |
| Allergan, INC. | $494.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $477.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $380.83 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $375.00 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Grifols USA, LLC | $372.91 | 2024-2025 | Hyperrab, Xembify |
| Gilead Sciences, INC. | $372.42 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $353.27 | 2023-2025 | |
| Pfizer INC. | $337.78 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $279.16 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $213.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $183.63 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $173.80 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $157.80 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $151.81 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $126.30 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $125.00 | 2025 | Nuzyra |
| Eisai INC. | $121.84 | 2025 | |
| Abbott Laboratories | $119.11 | 2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $52.22 | 2019 | |
| Currax Pharmaceuticals LLC | $32.51 | 2025 | Contrave |
| Genentech USA, INC. | $24.14 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Herbst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.